Murky Response Measures Shouldn’t Block Accelerated Approval Of GSK’s Arzerra, ODAC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Meeting at the ASCO annual meeting, the panel votes 10-3 that an ORR of 42 percent is likely to predict clinical benefit in chronic lymphocytic leukemia patients refractory to two drugs.
You may also be interested in...
Context Is Key To Accelerated Approval In Oncology, Arzerra Review Shows
By targeting a population with an unmet medical need that would qualify for review under FDA's accelerated approval regulations, GlaxoSmithKline and Genmab transcended a "suboptimal" development program and "uncertainty" regarding the magnitude of treatment effect to bring their anti-CD20 monoclonal antibody Arzerra (ofatumumab) to market, FDA review documents show
Context Is Key To Accelerated Approval In Oncology, Arzerra Review Shows
By targeting a population with an unmet medical need that would qualify for review under FDA's accelerated approval regulations, GlaxoSmithKline and Genmab transcended a "suboptimal" development program and "uncertainty" regarding the magnitude of treatment effect to bring their anti-CD20 monoclonal antibody Arzerra (ofatumumab) to market, FDA review documents show
Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK
Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.